Clinical trials: Recurrent GBM
Glioblastoma, Brain Tumor
Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma
Patients may participate in this research study if they have glioblastoma. (a brain tumor) that has come back after being treated. Standard treatment for this cancer is a chemotherapy drug called bevacizumab.
- Trial name
- NCT02768389
- Testing
- Bevacizumab, Modified Atkins Diet
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Case Comprehensive Cancer Center
Brain and Central Nervous System Tumors
Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma
RATIONALE: Drugs used in chemotherapy, such as tetra-O-methyl nordihydroguaiaretic acid (EM-1421), work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00404248
- Testing
- terameprocol, pharmacological study
- Where
- 9 sites in United States
- Volunteers
- 35 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
This randomized phase II trial studies how well bevacizumab with or without radiation therapy works in treating patients with recurrent glioblastoma.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT01730950
- Testing
- bevacizumab, radiation therapy
- Where
- 31 sites in United States
- Volunteers
- 182 people
- Sponsor
- Radiation Therapy Oncology Group
Brain Neoplasms, Central Nervous System Neoplasms
Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma
The goal of Part I of this clinical research study is to find the highest tolerable dose of TPI 287 that can be given with bevacizumab to patients with glioblastoma.
- Trial name
- NCT01582152
- Testing
- TPI287, Bevacizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
High Grade Glioma, Glioblastoma Multiforme
Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
This is a study of DSP-0390 in patients with recurrent high grade glioma.
- Trial name
- NCT05023551
- Testing
- DSP-0390
- Where
- 9 sites in United States, Japan
- Volunteers
- 39 people
- Sponsor
- Sumitomo Pharma America, Inc.
Brain and Central Nervous System Tumors
Phosphorus 32 in Treating Patients With Glioblastoma Multiforme
RATIONALE: Radioactive drugs such as phosphorus 32 may be able to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of phosphorus 32 in treating patients with glioblastoma multiforme.
- Trial name
- NCT00004129
- Testing
- brachytherapy, phosphorus P32
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Center for Molecular Medicine
Malignant Glioma, Recurrent Ependymoma
A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
This study will evaluate the administration of AdV-tk followed by valacyclovir in children with malignant glioma, including glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), as well as recurrent ependymomas in…
- Trial name
- NCT00634231
- Testing
- AdV-tk, valacyclovir, Radiation
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Candel Therapeutics, Inc.
Glioblastoma, Glioma
Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma
This phase I trial studies the side effects and best dose of ascorbic acid when given together with bevacizumab in treating patients with high grade glioma that has come back (recurrent).
- Trial name
- NCT02833701
- Testing
- Ascorbic Acid, Bevacizumab, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Nebraska
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
This phase II trial is studying how well giving erlotinib together with sorafenib works in treating patients with progressive or recurrent glioblastoma multiforme.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT00445588
- Testing
- erlotinib hydrochloride, sorafenib tosylate, pharmacological study
- Where
- 9 sites in United States
- Volunteers
- 56 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma, Glioma
A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
This open-label, multicenter, Phase I, dose-escalating study will evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics and efficacy of GDC-0084 in patients with progressive or recurrent high-grade glioma.
- Trial name
- NCT01547546
- Testing
- GDC-0084
- Where
- 5 sites in United States, Spain
- Volunteers
- 29 people
- Sponsor
- Genentech, Inc.
Glioblastoma Multiforme
Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme
This is an open-label, dose finding, multiple-dose study in subjects with recurring/relapsing glioblastoma multiforme. Three dose levels of MPC-6827 will be administered with carboplatin to three separate cohorts.
- Trial name
- NCT00635557
- Testing
- MPC-6827 + Carboplatin
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Myrexis Inc.
Adult Glioblastoma, Adult Gliosarcoma
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
This randomized phase II trial is studying the side effects and how well giving bevacizumab together with irinotecan or temozolomide works in treating patients with recurrent or refractory glioblastoma multiforme or gliosarcoma.
- Conditions
- Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
- Trial name
- NCT00433381
- Testing
- Bevacizumab, Irinotecan Hydrochloride, Temozolomide
- Where
- 93 sites in United States
- Volunteers
- 123 people
- Sponsor
- National Cancer Institute (NCI)
Astrocytoma, Glioblastoma
First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma
This is a single center, first-in cancer-type phase I clinical trial of FT536 for adult patients with recurrent WHO Grade 4 astrocytoma, irrespective of IDH-mutational status, for which a standard of care repeat craniotomy for…
- Conditions
- Astrocytoma, Glioblastoma, Progressive Disease
- Trial name
- NCT07560865
- Testing
- FT536, Biopsy/ Intratumoral Injection/ Gross Tumor Resection, Blood/ Cerebrospinal Fluid/ Tumor Pathology
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Glioma, Malignant
Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma
Glioblastoma is a highly aggressive and fatal form of primary malignant brain tumor with limited treatment options. fb-PMT affects a large group of cancer cell signaling pathways and thus may be effective in heterogeneous…
- Trial name
- NCT05226494
- Testing
- fb-PMT
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- NanoPharmaceuticals LLC
Glioblastoma
Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma
The purpose of this study is to determine whether bevacizumab and nimustine are effective in the treatment of recurrent high grade glioma and to explore whether there is any subgroup being sensitive to this therapeutic protocol.
- Trial name
- NCT02698280
- Testing
- Bevacizumab, Nimustine
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Huashan Hospital
Malignant Glioma
Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma
The purpose of this study is to assess the activity of Sym004, a recombinant antibody mixture that specifically binds to EGFR, in patients diagnosed with recurrent glioblastoma whose tumor is EGFR amplified.
- Trial name
- NCT02540161
- Testing
- Sym004 - 18 mg/kg, Sym004 - 24 mg/kg
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Annick Desjardins
Recurrent Anaplastic Astrocytoma, Recurrent Anaplastic Oligoastrocytoma
Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
This phase I trial studies the side effects and best dose of carboxylesterase-expressing allogeneic neural stem cells when given together with irinotecan hydrochloride in treating patients with high-grade gliomas that have come…
- Conditions
- Recurrent Anaplastic Astrocytoma, Recurrent Anaplastic Oligoastrocytoma, Recurrent Anaplastic Oligodendroglioma, Recurrent Glioblastoma
- Trial name
- NCT02192359
- Testing
- Carboxylesterase-expressing Allogeneic Neural Stem Cells, Irinotecan, Irinotecan Hydrochloride
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
Brain and Central Nervous System Tumors
Pharmacologic Study of Methotrexate in Patients Undergoing Stereotactic Biopsy for Recurrent High-Grade Glioma
RATIONALE: Collecting fluid from a brain tumor using a small catheter may help doctors learn how much methotrexate gets into the tumor to kill the tumor cells.
- Trial name
- NCT00463008
- Testing
- methotrexate, pharmacological study
- Volunteers
- 12 people
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
Glioblastoma
Metronomic Temozolamide in Patients With Recurrent Glioblastoma
Indication: Subjects with glioblastoma at first relapse after surgery, radiotherapy and first-line temozolomide (TMZ). Objectives: 1.
- Trial name
- NCT01308632
- Testing
- Temozolamide, irinotecan
- Volunteers
- 30 people
- Sponsor
- Grupo Español de Investigación en Neurooncología
Recurrent GBM
Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut
Celldex endeavors to make investigational products available to patients with life-threatening diseases who have exhausted other treatment options and where there is a reasonable expectation of benefit over risk.
- Trial name
- CDX-110 (NCT03068650)
- Testing
- rindopepimut
- Sponsor
- Celldex Therapeutics